

ASCO 2002 ABSTRACTS

1. Kouno T, Shimizu C, Watanabe T, Tsuda H, Kurosumi M, Akiyama F, Sakamoto G. A reliable nuclear grading system for primary breast cancer (BC) for selecting high risk invasive ductal carcinoma (IDC) among node negative (NO) patients: The National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Panel. ASCO 2003;Abstract No.113.
2. Matsumoto K, Katsumata N, Andoh M, Yamanaka Y, Kitagawa R, Shimizu C, Mukai H, Tokunaga S, Kohno T, Watanabe T; National Cancer Center Hospital, Tokyo, Japan. Efficacy of irinotecan in patients with platinum and taxane-resistant ovarian cancer. ASCO 2003;Abstract No.1863.
3. Shimizu C, Kitagawa R, Yamanaka Y, Tokunaga S, Katsumata N; National Cancer Center Hospital, Tokyo, Japan. A safety and efficacy trial of docetaxel (D) and cisplatin (P) in patients with cancer of unknown primary (CUP). ASCO 2003;Abstract No.2597.
4. Tokunaga S, Andoh M, Watanabe T, Shimizu C, Katsumata N, Fujiwara Y; National Cancer Center Hospital, TOKYO, Japan. Neurotoxicity is enhanced when DD (DOX: Doxorubicin, DTX: docetaxel) and weekly paclitaxel (w-PTX) +/- trastuzumab (H) are given sequentially as primary chemotherapy (PTC) in patients (pts) with operable breast cancer. ASCO 2003;Abstract No.124.
5. Arai T, Hamaguchi T, Shirao K, Shimada Y, Yamada Y, Muro K, Matsumura Y, Ura T, Goto A. Weekly paclitaxel in patients with heavily treated advanced gastric cancer. ASCO 2003;Abstract No.1291.
6. Goto A, Yamada Y, Yasui H, Shirao K, Shimada Y, Muro K, Hamaguchi T, Arai T, Ura T, Shimoda T. Expression of HER2 in patients with gastric cancer. ASCO 2003;Abstract No.1290.
7. Hamaguchi T, Matsumura Y, Shirao K, Shimada Y, Yamada Y, Muro K, Okusaka T, Ueno H, Ikeda M, Watanabe N. Phase I Study of novel drug delivery system, NK911, a polymer micelle encapsulated doxorubicin. ASCO 2003;Abstract No.571
8. Hyodo I, Shirao K, Boku N, Ohtsu A, Miyata Y, Nakagawa K, Tamura T, Hatake K, Tanigawara Y. Phase II trial and pharmacokinetic analysis of oxaliplatin(L-OHP) as secondline treatment in patients(pts) with metastatic colorectal cancer (MCRC). ASCO 2003;Abstract No.1383.
9. Ishikura S, Ohtsu A, Shirao K, Muro K, Kagami Y, Nihei K, Mera K, Ito Y. A phase I/II study of nedaplatin and 5-fluorouracil eith concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group study(JCOG9908-DI). ASCO 2003;Abstract No.1106.
10. Muro K, Ando N, Nishimaki T, Ohtsu A, Aogi K, Aoyama K, Ngai K, Kato H. A phase II study of nedaplatin and 5-fluorouracil in metastatic spuamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group(JCOG) tria (JCOG9905). ASCO 2003;Abstract No.1112.
11. Ura T, Yamada Y, Shimada Y, Matsumura Y, Muro K, Hamaguchi T, Arai T, Hosokawa A, Goto A, Shirao K. A Phase 1/2 study of modified combination chemotherapy of Saltz regimen for metastatic colorectal cancer. ASCO 2003;Abstract No.1261.
12. Yamada Y, Goto A, Ura T, Arai T, Hamaguchi T, Muro K, Shimada Y, Shirao K. Phase I and pharmacokinetic study of S-1 in combination with CPT-11 for advanced gastric cancer. ASCO 2003;Abstract No.1314.
13. Arima F, Tobinai K, Takeyama K, Mikuni C, Hanada S, Kasai M, Fukuda H, Shirakawa S, Shimoyama M, Hotta T: Improved results with granulocyte colony-stimulating factor (G-CSF)-supported, intensive

- post-remission chemotherapy for adult patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): Japan Clinical Oncology Group study 9004. ASCO 2003;Abstract No. 2365.
14. Hotta T, Shimakura Y, Ishizuka N, Fukuda H, Itoh K, Morishima Y, Suzuki T, Ueda R, Shimoyama M, Tobinai K: Randomized phase III study of standard CHOP versus biweekly CHOP in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group study, JCOG9809. ASCO 2003;Abstract No. 2271.
 15. Ogura M, Morishima Y, Itoh K, Ishizawa K, Kobayashi Y, Tobinai K, Kinoshita T, Hirano M, Ueda R, Fukuda H, Hotta T, Shimoyama M: Phase II study of ABV therapy followed by involved-field irradiation for advanced stage Hodgkin's disease in Japan: Japan Clinical Oncology Group study (JCOG9705). ASCO 2003;Abstract No. 2303.
 16. Tobinai K, Watanabe T, Hotta T, Ogawa Y, Sasaki Y, Minami H, Morishima Y, Ogura M, Seriu T: Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma (B-NHL). ASCO 2003;Abstract No. 2411.
 17. Okusaka T, Ito, Y., Ueno H, Ikeda M, Takezako, Y., Kawauchi, S., Kagami, Y., Ikeda, H., Okada, S. Phase II trial of chemoradiotherapy using gemcitabine (GEM) in patients with locally advanced pancreatic cancer. ASCO 2003; Abstract No.1203.
 18. Ueno, H., Okusaka T, Ikeda, M., Kuriyama, H., Saisho, T., Morizane, C., Okada, S. A phase II and pharmacokinetic trial of S-1 in patients with advanced biliary tract cancer (BTC). ASCO 2003;Abstract No.1355.
 19. Hosono A, Makimoto A, Kawamoto H, Sakiyama M, Matsubara H, Yokoyama R, Beppu Y, Ohira M. A retrospective analysis in safety and efficacy of protracted administration of irinotecan for patients with small round cell sarcomas relapsed after stem cell transplantation (SCT). ASCO 2003;Abstract No.3269.
 20. Makimoto A, Kami M, Mineishi S, Tanosaki R, Kanda Y, Kim SW, Hori A, Heike Y, Takaue Y, Kakizoe T. Reduced-intensity stem cell transplantation (RIST) for patients including children with refractory sarcomas. ASCO 2003;Abstract No.3355.
 21. Fujiwara Y, Ohe Y, Minami M, Shimoyama M, Fukuda H, Shimada Y, Eguchi K, Tobinai K, Saijo N. N Saijo. The Japan Clinical Oncology Group (JCOG) audit system for clinical trials. ASCO 2003;Abstract No.2233.
 22. Kunitoh H, Kato H, Tsuboi M, Ishizuka N, Tsuchiya R, Ichinose Y, Katakami N, Saijo N. A phase II trial of pre-operative chemoradiotherapy followed by surgical resection in pancoast tumors: Initial report of Japan Clinical Oncology Group trial (JCOG 9806). ASCO 2003;Abstract No.2549.
 23. Minami H, Ebi H, Tahara M, Sasaki Y, Yamamoto N, Yamada Y, Tamura T, Saijo N. A Phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. ASCO 2003;Abstract No.776.
 24. Murakami H, Yamamoto N, Shimoyama T, Ueda Y, Yamada Y, T Tamura. Phase I, Pharmacokinetic, and biological studies of TSU-68, the oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, administered after meals in patients with advanced solid tumors. ASCO 2003;Abstract No.870.
 25. Negoro S, Ohe Y, Matsui K, Nakagawa K, Sugiura T, Ohbayashi K, Nishiwaki Y, Saijo N, Fukuoka

- M, Ariyoshi Y. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ED-SCLC). ASCO 2003;Abstract No.2608.
26. Niho S, Ohe Y, Yokoyama A, Watanabe K, Saijo N, Nishiwaki Y. A phase II study of docetaxel (D) and cisplatin (C) (DC) administered as three consecutive weekly infusions in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC). ASCO 2003;Abstract No.2732.
 27. Ohe Y, Saijo N, Ohashi Y, Nishiwaki Y, Nakagawa K, Tamura T, Negoro S, Kubota K, Ariyoshi Y, Fukuoka M. Preliminary results of the four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC) in Japan. ASCO 2003;Abstract No.2509.
 28. Saijo N. Expert Opinion: Small cell lung cancer? Current therapy and novel agents. ASCO 2003;Education Program.
 29. Yamamoto N, Yamada Y, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Takayama K, Sakamoto T, Hoshida M, Tamura T. A phase I study of erlotinib HCl in Japanese patients with types of solid tumors. ASCO 2003;Abstract No.903.
 30. Kato H, Udagawa H, Togo A, Ando N, Tanaka O, Shinoda M, Aogi K, Yamana H, Shimizu H, Fukuda H, for the Japan Clinical Oncology Group (JCOG). A phase II trial of chemo-radiotherapy in patients with stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group study (JCOG9708). ASCO2003;Abstract No. 1147.
 31. Kawai A, Umeda T, Hasegawa T, Wada T, Ihara K, Isu K, Abe S, Kawano H, Tsugane S, Beppu Y. Ifosfamide(IFM), Doxorubicin (D) and cyclophosphamide chemotherapy for advanced adult soft tissue sarcoma: aJapanese Musculoskeletal Oncology Group (JMOG) study. ASCO 2003;Abstract No. 3316.